Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (belamaf).

被引：0
|
作者：
Terpos, Evangelos
Badros, Ashraf
Popat, Rakesh
Rodriguez-Otero, Paula
Farooq, Asim
Jeng, Bennie
Esposti, Simona Degli
Lewis, Eric
Gupta, Ira
Opalinska, Joanna
Palumbo, Antonio
Trudel, Suzanne
机构：
[1] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece
[2] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
[3] Univ Coll London Hosp, NHS Fdn Trust, London, England
[4] Clin Univ Navarra, Inst Invest Sanitaria Navarra, Navarra, Spain
[5] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[6] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England
[7] UCL Inst Ophthalmol, London, England
[8] GlaxoSmithKline, Res Triangle Pk, NC USA
[9] GlaxoSmithKline, Upper Providence, PA USA
[10] GlaxoSmithKline, Zug, Switzerland
[11] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.8033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8033
引用
收藏
页数：4
相关论文
共 34 条
  • [11] Characteristics of Patients and Management of Ocular Adverse Events After Treatment With Belantamab Mafodotin (Belamaf) in Relapsed/ Refractory Multiple Myeloma (RRMM): A Real-World Study in Europe
    Cavo, Michele
    Delforge, Michel
    Dimopoulos, Meletios
    Escalante-Barrigon, Fernando
    Hultcrantz, Malin
    Kleinman, David
    Lee, Hans
    Vij, Ravi
    Greil, Richard
    Melchardt, Thomas
    Antonioli, Elisabetta
    Schjesvold, Fredrik
    Lysen, Anna
    Kotowsky, Nirali
    Camadoo-O'Byrne, Leena
    Bitetti, Jacopo
    Mouro, Jorge
    D'Estrube, Tim
    Fry, Mark
    Byrne, Julie
    Vossen, Carla
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S277 - S278
  • [12] Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin
    Popat, Rakesh
    Badros, Ashraf Z.
    Kumar, Shaji
    Rodríguez-Otero, Paula
    Cohen, Adam D.
    Manier, Salomon
    Voorhees, Peter M.
    Gay, Francesca
    Rifkin, Robert M.
    Martin, Thomas
    Chari, Ajai
    Weisel, Katja
    Farooq, Asim V.
    Jeng, Bennie H.
    Chng, Wee Joo
    Lee, Hans C.
    Berdeja, Jesus
    Jadhav, Vinay
    Tosolini, Alessandra
    Eliason, Laurie
    Palumbo, Antonio
    Dimopoulos, Meletios A.
    Lonial, Sagar
    Trudel, Suzanne
    Richardson, Paul G.
    Terpos, Evangelos
    BLOOD, 2021, 138
  • [13] Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Richardson, Paul G.
    Nooka, Ajay
    Quach, Hang
    Trudel, Suzanne
    Routledge, David
    Song, Kevin
    Nahi, Hareth
    Paul, Sofia
    Khan, Josephine
    Brouch, Maria
    Ferron-Brady, Geraldine
    Yeakey, Anne
    Shelton, Chris
    de Oca, Rocio Montes
    Smith, L. Mary
    Im, Ellie
    Ahlers, Christoph M.
    Paul, Elaine M.
    Holkova, Beata
    Gupta, Ira
    Kremer, Brandon E.
    Rodriguez-Otero, Paula
    BLOOD, 2020, 136
  • [14] METHODOLOGY FOR EVALUATING MEANINGFUL CHANGE THRESHOLDS IN PATIENT-REPORTED OUTCOME (PRO) MEASURES FOR CORNEAL EVENTS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) RECEIVING SINGLE-AGENT BELANTAMAB MAFODOTIN (BELAMAF)
    Eliason, L.
    Loubert, A.
    Gorsh, B.
    Meunier, J.
    Kleinman, D.
    Sapra, S.
    Regnault, A.
    VALUE IN HEALTH, 2020, 23 : S477 - S477
  • [15] DREAMM-2: Single-agent belantamab mafodotin (belamaf; GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) - outcomes by prior therapies
    Weisel, K.
    Lonial, S.
    Lee, H.
    Badros, A.
    Trudel, S.
    Nooka, A.
    Chari, A.
    Abdallah, A-O
    Callander, N.
    Sborov, D.
    Suvannasankha, A.
    Vorhees, P.
    Opalinska, J.
    Hoos, A.
    Zhi, E.
    Baron, J.
    Piontek, T.
    Jewell, R.
    Gupta, I
    Cohen, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 109 - 110
  • [16] Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Nooka, Ajay
    Lee, Hans C.
    Badros, Ashraf Z.
    Voorhees, Peter
    Hultcrantz, Malin
    Karlin, Lionel
    Arnulf, Bertrand
    Richardson, Paul G.
    Zhi, Eric
    Baron, January
    Piontek, Trisha
    Lewis, Eric
    Opalinska, Joanna
    Gupta, Ira
    Cohen, Adam D.
    Lonial, Sagar
    BLOOD, 2020, 136
  • [17] DREAMM-2: Belantamab mafodotin (belamaf; GSK2857916) effect on disease symptoms and health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM)
    Weisel, K.
    Popat, R.
    Lonial, S.
    Lee, H.
    Badros, A.
    Trudel, S.
    Nooka, A.
    Chari, A.
    Abdallah, A-O
    Callander, N.
    Sborov, D.
    Suvannasankha, A.
    Voorhees, P.
    Cohen, A.
    Opalinska, J.
    Gutierrez, B.
    Gorsh, B.
    He, Z.
    Eliason, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 103 - 104
  • [18] Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Lonial, Sagar
    Nooka, Ajay
    Thulasi, Praneetha
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Callander, Natalie S.
    Sborov, Douglas
    Zaugg, Brian E.
    Popat, Rakesh
    Degli Esposti, Simona
    Byrne, Julie
    Opalinska, Joanna
    Baron, January
    Piontek, Trisha
    Gupta, Ira
    Dana, Reza
    Farooq, Asim
    Jakubowiak, Andrzej
    BLOOD, 2020, 136
  • [19] DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Rifkin, Robert M.
    Boyd, Kevin
    Grosicki, Sebastian
    Kim, Kihyun
    Di Raimondo, Francesco
    Dimopoulos, Meletios A.
    Weisel, Katja
    Arnulf, Bertrand
    Hajek, Roman
    Hungria, Vania T. M.
    Spencer, Andrew
    Davis, Randy
    Riccio, Antonio
    Kim, Chanbin
    Wilkes, Jodie
    Rutledge, Ruth
    Talekar, Mala
    Kremer, Brandon E.
    Gupta, Ira
    Mateos, Maria-Victoria
    BLOOD, 2020, 136
  • [20] DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM)
    Richardson, Paul G.
    Trudel, Suzanne
    Callander, Natalie S.
    Nooka, Ajay
    Song, Kevin
    Uttervall, Katarina
    Minnema, Monique C.
    Rodriguez-Otero, Paula
    Struemper, Herbert
    Yeakey, Anne
    de Oca, Rocio Montes
    Smith, L. Mary
    Jackson, Nicola
    Kaisermann, Morrys
    Im, Ellie
    Basile, Frank G.
    Ahlers, Christoph M.
    Holkova, Beata
    Gupta, Ira
    Kremer, Brandon E.
    Quach, Hang
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S156 - S156
1234